Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.
Previous studies have demonstrated that locally administered cannabinoids attenuate allodynia and hyperalgesia through activation of peripheral cannabinoid receptors (CB(1) and CB(2)). However, it is currently unknown if cannabinoids alter the response properties of nociceptors. In the present study, correlative behavioral and in vivo electrophysiological studies were conducted to determine if peripheral administration of the cannabinoid receptor agonists arachidonyl-2'-chloroethylamide (ACEA) or (R)-(+)-methanandamide (methAEA) could attenuate mechanical allodynia and hyperalgesia, and decrease mechanically evoked responses of Adelta nociceptors. Twenty-four hours after intraplantar injection of complete Freund's adjuvant (CFA), rats exhibited allodynia (decrease in paw withdrawal threshold) and hyperalgesia (increase in paw withdrawal frequency), which were attenuated by both ACEA and methAEA. The antinociceptive effects of these cannabinoids were blocked by co-administration with the CB(1) receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophen yl)-4-methyl-1H-pyrazole-3-carboxamide (AM251) but not with the CB(2) receptor antagonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-y l](4-methoxyphenyl)methanone (AM630). ACEA and methAEA did not produce antinociception under control, non-inflamed conditions 24 h after intraplantar injection of saline. In parallel studies, recordings were made from cutaneous Adelta nociceptors from inflamed or control, non-inflamed skin. Both ACEA and methAEA decreased responses evoked by mechanical stimulation of Adelta nociceptors from inflamed skin but not from non-inflamed skin, and this decrease was blocked by administration of the CB(1) receptor antagonist AM251. These results suggest that attenuation of mechanically evoked responses of Adelta nociceptors contributes to the behavioral antinociception produced by activation of peripheral CB(1) receptors during inflammation.
Potenzieri
Carl
C
Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, 515 Delaware St. SE, 17-252 Moos Tower, Minneapolis, MN 55455, USA.
Brink
Thaddeus S
TS
Pacharinsak
Cholawat
C
Simone
Donald A
DA
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D000704:Analysis of Variance; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D002186:Cannabinoids / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005620:Freund's Adjuvant; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D009413:Nerve Fibers, Myelinated / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology; D009619:Nociceptors / Q000378:metabolism*; D010147:Pain Measurement / Q000379:methods; D017288:Pain Threshold / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors; D012867:Skin / Q000294:innervation*
D001095:Arachidonic Acids; D002186:Cannabinoids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; C119325:arachidonyl-2-chloroethylamide; C103505:AM 251; D005620:Freund's Adjuvant
J Immunol. 2001 Jun 15;166(12):7183-9
11390466
Anesthesiology. 1988 Apr;68(4):571-90
3281512
Eur J Neurosci. 2005 Jul;22(2):371-9
16045490
Eur J Neurosci. 1999 May;11(5):1698-704
10215923
Br J Pharmacol. 2004 Apr;141(7):1118-30
15006899
Inflammopharmacology. 2004;12(2):99-114
15265314
J Neurosci. 1982 Jun;2(6):765-81
7086482
Neuroscience. 2006 Feb;137(3):999-1013
16330152
Eur J Neurosci. 2004 Nov;20(9):2311-20
15525273
J Pharmacol Exp Ther. 1999 Jun;289(3):1427-33
10336536
Science. 1981 Sep 25;213(4515):1527-9
7280675
Neuropharmacology. 2001;40(2):221-32
11114401
Neuroscience. 1999 Mar;90(3):923-31
10218792
Pain. 1998 Mar;75(1):111-119
9539680
Neuropharmacology. 2006 Jun;50(7):814-23
16442133
Chem Phys Lipids. 2002 Dec 31;121(1-2):173-90
12505699
Eur J Pharmacol. 2008 May 31;586(1-3):160-3
18410918
Neuroscience. 2000;100(4):685-8
11036202
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3093-8
15705714
Brain Res. 2008 Jun 18;1215:69-75
18486111
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10529-33
12917492
J Biol Chem. 2003 Sep 5;278(36):33896-903
12815050
Life Sci. 1995;56(23-24):1949-55
7776818
J Neurosci Methods. 1994 Jul;53(1):55-63
7990513
Neuroscience. 2003;119(3):747-57
12809695
J Neurophysiol. 1984 Feb;51(2):325-39
6707724
J Pharmacol Exp Ther. 2004 Feb;308(2):446-53
14610224
J Immunol. 2003 May 15;170(10):4953-62
12734338
Neurosci Lett. 2008 Mar 12;433(2):77-81
18242856
J Med Chem. 1994 Jun 10;37(12):1889-93
8021930
Pain. 2001 May;92(1-2):91-100
11323130
Nature. 1993 Sep 2;365(6441):61-5
7689702
J Dermatol Sci. 2005 Jun;38(3):177-88
15927811
Pain. 2006 Dec 15;126(1-3):102-14
16844297
Pharmacol Ther. 2002 Aug;95(2):127-35
12182960
Pain. 2006 Sep;124(1-2):175-83
16709443
Br J Pharmacol. 2008 Jan;153(2):319-34
17994113
Life Sci. 1997;61(9):PL115-8
9284087
Br J Pharmacol. 2002 Oct;137(4):421-8
12359623
J Neurophysiol. 1999 Nov;82(5):2649-56
10561434
Biochem J. 2000 Mar 15;346 Pt 3:835-40
10698714
J Neurosci. 2006 Jan 25;26(4):1281-92
16436616
J Neurophysiol. 2004 Dec;92(6):3562-74
15317842
Pain. 2005 Dec 5;118(3):327-335
16289798
Anesthesiology. 2008 Apr;108(4):669-74
18362599
Nat Neurosci. 2007 Jul;10(7):870-9
17558404
Eur J Biochem. 2002 Aug;269(15):3771-8
12153574
Neuroscience. 2003;119(3):803-12
12809701
Pain. 2006 Mar;121(1-2):85-93
16480822
J Neurophysiol. 1983 Jul;50(1):1-26
6875640
J Neurophysiol. 1993 May;69(5):1684-99
8509832
J Neurophysiol. 2002 Feb;87(2):712-20
11826040
J Neurophysiol. 2006 Apr;95(4):2083-97
16339007
Life Sci. 1999;65(6-7):637-44
10462064
Neuropharmacology. 2003 Sep;45(3):404-11
12871657
Prog Neurobiol. 1992;38(4):397-421
1574584
Anesthesiology. 2003 Oct;99(4):955-60
14508331
Life Sci. 1999;65(6-7):665-73
10462067
Neuroscience. 2002;115(2):613-25
12421626
J Neurosci. 2004 Feb 18;24(7):1744-53
14973253
J Leukoc Biol. 2003 Oct;74(4):486-96
12960289
Br J Pharmacol. 2007 Jan;150(2):153-63
17160008
Pain. 2008 Sep 15;138(3):667-680
18692962
Nature. 1998 Jul 16;394(6690):277-81
9685157
Eur J Pharmacol. 2001 Jul 27;424(3):211-9
11672565
Pain. 2004 Jun;109(3):432-442
15157704
Curr Pharm Des. 2006;12(24):3135-46
16918439
Eur J Pharmacol. 1996 Jul 4;307(3):331-8
8836622
Br J Pharmacol. 2001 Mar;132(5):969-71
11226126
Pain. 1987 Jun;29(3):363-373
3614971
J Neurophysiol. 1969 Nov;32(6):1025-43
5347705
Pain. 2001 Sep;93(3):303-315
11514089
J Neurophysiol. 2002 Feb;87(2):721-31
11826041
Pain. 2006 May;122(1-2):36-42
16563625
Neuropharmacology. 2004;47 Suppl 1:345-58
15464149
Neuroscience. 2003;118(2):547-62
12699789
Pain. 2002 Jul;98(1-2):59-68
12098617
Neurosci Lett. 1990 Mar 26;111(1-2):206-10
2336185
Nature. 1990 Aug 9;346(6284):561-4
2165569
Pain. 2001 Sep;93(3):239-245
11514083